Literature DB >> 6805423

Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosa.

C W Norden, M A Shaffer.   

Abstract

Azlocillin and tobramycin were used alone and in combination in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits. This combination showed in vitro synergy measured by both the checkerboard technique and time-kill curves. A marked inoculum effect was demonstrated in vitro with azlocillin and the infecting strain of P. aeruginosa. The minimal inhibitory concentration of azlocillin, with an inoculum of 10(5) organisms, was 12.5 micrograms/ml; when the inoculum size was increased to 10(7) organisms, the minimal inhibitory concentration rose to more than 500 micrograms/ml. In therapeutic trials, the combination of azlocillin and tobramycin, given for 28 days, was significantly better than either no therapy or azlocillin alone, but was not significantly better than tobramycin alone. Even after 4 weeks of combined therapy with azlocillin and tobramycin, P. aeruginosa was recovered from the bones of 60% of the treated rabbits.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6805423      PMCID: PMC181830          DOI: 10.1128/AAC.21.1.62

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Experimental osteomyelitis. I. A description of the model.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1970-11       Impact factor: 5.226

2.  Azlocillin: in vitro studies of a new semisynthetic penicillin.

Authors:  D Stewart; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

3.  Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, and ticarcillin.

Authors:  L Coppens; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

4.  Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

5.  Azlocillin and mezlocillin: new ureido penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

6.  Experimental osteomyelitis caused by Pseudomonas aeruginosa.

Authors:  C W Norden; E Keleti
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

7.  Experimental osteomyelitis due to Staphylococcus aureus or Pseudomonas aeruginosa: a radiographic-pathological correlative analysis.

Authors:  C W Norden; R L Myerowitz; E Keleti
Journal:  Br J Exp Pathol       Date:  1980-08

8.  Comparative bactericidal effects of azlocillin and ticarcillin against Pseudomonas aeruginosa.

Authors:  A R White; K R Comber; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

  8 in total
  8 in total

Review 1.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

2.  Vancomycin concentrations in infected and noninfected human bone.

Authors:  A L Graziani; L A Lawson; G A Gibson; M A Steinberg; R R MacGregor
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

3.  High-pressure liquid chromatographic quantitation of azlocillin.

Authors:  A Weber; K E Opheim; K Wong; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumonia.

Authors:  F M Gordin; M G Rusnak; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

5.  Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.

Authors:  L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

6.  Time-survival studies for quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosa.

Authors:  M M McFarland; E M Scott; A Li Wan Po
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

7.  Azlocillin and cefonicid penetration into bone enhanced by probenecid.

Authors:  J T Summersgill; L G Harrod; M J Raff
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

8.  Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.

Authors:  N X Chin; K Jules; H C Neu
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.